MML Investors Services LLC Has $618,000 Stock Holdings in Insulet Co. (NASDAQ:PODD)

MML Investors Services LLC lifted its position in shares of Insulet Co. (NASDAQ:PODD) by 9.3% in the third quarter, Holdings Channel reports. The institutional investor owned 2,655 shares of the medical instruments supplier’s stock after acquiring an additional 225 shares during the period. MML Investors Services LLC’s holdings in Insulet were worth $618,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of PODD. QRG Capital Management Inc. acquired a new stake in Insulet in the 3rd quarter worth about $297,000. Fisher Asset Management LLC increased its holdings in shares of Insulet by 0.9% during the third quarter. Fisher Asset Management LLC now owns 351,100 shares of the medical instruments supplier’s stock worth $81,719,000 after purchasing an additional 3,113 shares during the period. Orion Portfolio Solutions LLC raised its position in shares of Insulet by 86.2% in the third quarter. Orion Portfolio Solutions LLC now owns 7,826 shares of the medical instruments supplier’s stock valued at $1,822,000 after buying an additional 3,623 shares in the last quarter. Point72 DIFC Ltd bought a new stake in shares of Insulet in the second quarter valued at approximately $554,000. Finally, GSA Capital Partners LLP bought a new position in Insulet during the 3rd quarter worth $1,017,000.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on PODD. Sanford C. Bernstein assumed coverage on Insulet in a research report on Wednesday, November 6th. They set an “outperform” rating and a $300.00 target price for the company. Raymond James increased their price objective on shares of Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a research note on Monday, October 14th. Piper Sandler boosted their target price on shares of Insulet from $230.00 to $285.00 and gave the company an “overweight” rating in a research report on Tuesday, September 17th. Citigroup increased their price target on shares of Insulet from $283.00 to $310.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a research report on Thursday, December 12th. Three investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $269.40.

Insider Buying and Selling

In other news, CAO Lauren Budden sold 915 shares of the firm’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the completion of the transaction, the chief accounting officer now owns 5,733 shares of the company’s stock, valued at approximately $1,580,129.46. This trade represents a 13.76 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.47% of the stock is owned by corporate insiders.

Insulet Stock Performance

NASDAQ:PODD opened at $266.57 on Friday. The stock’s 50-day moving average is $254.48 and its 200-day moving average is $222.96. Insulet Co. has a 1-year low of $160.19 and a 1-year high of $279.77. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The stock has a market cap of $18.70 billion, a P/E ratio of 45.65, a price-to-earnings-growth ratio of 4.12 and a beta of 1.21.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.